References
- Doenhoff MJ, Hagan P, Cioli D et al. Praziquantel: its use in control of schistosomiasis in sub-Saharan Africa and current research needs. Parasitology 136(13), 1825–1835 (2009).
- Kramers PG, Gentile JM, Gryseels BJ et al. International Commission for Protection Against Environmental Mutagens and Carcinogens. ICPEMC publication No. 18. Review of the genotoxicity and carcinogenicity of antischistosomal drugs; is there a case for a study of mutation epidemiology? Report of a task group on mutagenic antischistosomals. Mutat. Res. 257(1), 49–89 (1991).
- Olliaro PL, Vaillant MT, Belizario VJ et al. A multicentre randomized controlled trial of the efficacy and safety of single-dose praziquantel at 40 mg/kg vs. 60 mg/kg for treating intestinal schistosomiasis in the Philippines, Mauritania, Tanzania and Brazil. PLoS Negl. Trop. Dis. 5(6), e1165 (2011).
- Fenwick A, Savioli L, Engels D, Robert Bergquist N, Todd MH. Drugs for the control of parasitic diseases: current status and development in schistosomiasis. Trends Parasitol. 19(11), 509–515 (2003).
- Cioli D, Pica-Mattoccia L, Archer S. Antischistosomal drugs: past, present ... and future? Pharmacol. Ther. 68(1), 35–85 (1995).
- Sabah AA, Fletcher C, Webbe G, Doenhoff MJ. Schistosoma mansoni: chemotherapy of infections of different ages. Exp. Parasitol. 61(3), 294–303 (1986).
- Stelma FF, Talla I, Sow S et al. Efficacy and side effects of praziquantel in an epidemic focus of Schistosoma mansoni. Am. J. Trop. Med. Hyg. 53(2), 167–170 (1995).
- Woelfle M, Seerden JP, de Gooijer J, Pouwer K, Olliaro P, Todd MH. Resolution of praziquantel. PLoS Negl. Trop. Dis. 5(9), e1260 (2011).
- Greenberg RM. Are Ca2+ channels targets of praziquantel action? Int. J. Parasitol. 35(1), 1–9 (2005).
- Nogi T, Zhang D, Chan JD, Marchant JS. A novel biological activity of praziquantel requiring voltage-operated Ca2+ channel beta subunits: subversion of flatworm regenerative polarity. PLoS Negl. Trop. Dis. 3(6), e464 (2009).
- Pica-Mattoccia L, Orsini T, Basso A et al. Schistosoma mansoni: lack of correlation between praziquantel-induced intra-worm calcium influx and parasite death. Exp. Parasitol. 119(3), 332–335 (2008).
- Doenhoff MJ. Is schistosomicidal chemotherapy sub-curative? Implications for drug resistance. Parasitol. Today 14, 434–435 (1998).
- Botros S, Sayed H, Amer N, El-Ghannam M, Bennett JL, Day TA. Current status of sensitivity to praziquantel in a focus of potential drug resistance in Egypt. Int. J. Parasitol. 35(7), 787–791 (2005).
- Helleberg M, Thybo S. High rate of failure in treatment of imported schistosomiasis. J.Travel Med. 17(2), 94–99 (2010).
- Sabah AA, Fletcher C, Webbe G, Doenhoff MJ. Schistosoma mansoni: reduced efficacy of chemotherapy in infected T-cell-deprived mice. Exp. Parasitol. 60(3), 348–354 (1985).
- Silva IM, Thiengo R, Conceição MJ et al. Therapeutic failure of praziquantel in the treatment of Schistosoma haematobium infection in Brazilians returning from Africa. Mem. Inst. Oswaldo Cruz 100(4), 445–449 (2005).
- Cioli D, Botros SS, Wheatcroft-Francklow K et al. Determination of ED50 values for praziquantel in praziquantel-resistant and -susceptible Schistosoma mansoni isolates. Int. J. Parasitol. 34(8), 979–987 (2004).
- Fallon PG, Doenhoff MJ. Drug-resistant schistosomiasis: resistance to praziquantel and oxamniquine induced in Schistosoma mansoni in mice is drug specific. Am. J. Trop. Med. Hyg. 51(1), 83–88 (1994).
- Valle C, Troiani AR, Festucci A et al. Sequence and level of endogenous expression of calcium channel β subunits in Schistosoma mansoni displaying different susceptibilities to praziquantel. Mol. Biochem. Parasitol. 130(2), 111–115 (2003).
- Hotez PJ, Fenwick A. Schistosomiasis in Africa: an emerging tragedy in our new global health decade. PLoS Negl. Trop. Dis. 3, e485 (2009).